Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

3 Nov 2015 07:00

RNS Number : 2905E
Biome Technologies PLC
03 November 2015
Β 

03 November 2015

Β 

Β 

Biome Technologies plc

("Biome", the "Company" or the "Group")

Β 

Trading Update

Β 

Β 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes its trading update for the nine-month period ended 30 September 2015.Β 

Total Group revenues achieved in Q3 were Β£1.3m, 169% ahead of the same quarter last year (2014: Β£0.5m). This takes Group revenues for the nine months to 30 September 2015 to Β£3.3m, 18% ahead of the prior year period (2014: Β£2.8m).

The Group made a small profit before interest, tax, depreciation, amortisation, and share option charges in the third quarter (based on unaudited management accounts).

Β 

This performance meets one of the Group's long-term strategic KPIs, established in March 2014, of passing the 'earnings positive' inflexion point in quarterly trading during 2015.

The Group's cash position as at 30 September 2015 was Β£1.7m (30 June 2015: Β£1.8m).

Bioplastics Division

Β 

Revenues in the Bioplastics division in Q3 were Β£0.5m (Q3 2014: Β£0.1m) reflecting, amongst other factors, stability in the US single-serve coffee market compared to the downturn seen in the second half of 2014.

Β 

A new product line comprising temperature-tolerant materials suitable for injection moulding has reached commercialisation and first shipments were made during the quarter. Management expect that revenues from these products will build in the coming months.

Β 

To complement the division's existing product range, a further product is being developed for a non-woven biodegradable mesh suitable for liquid filtration. This product is in the process of being tested by several end customers with encouraging initial results.

Β 

Forward order visibility for the division is encouraging for the remainder of the year.

Β 

Stanelco RF Technologies Division

Β 

Revenues for Q3 in the RF Technologies division were Β£0.8m (Q3 2014: Β£0.4m). This year's orders and shipments are weighted towards the second half and this revenue growth includes elements of the recently announced Β£1.1m contract to supply multiple furnaces, as well as progress on the contract announced last year to supply advanced analytical equipment to a UK regulated-industry sector.

Β 

Order levels within the division remain high with a substantial pipeline stretching beyond the remainder of the year and into 2016.

Β 

Outlook

Β 

Revenues and order flow in both divisions remain encouraging and the Board is now confident that Group revenues for the year ending 31 December 2015 will show a meaningful improvement against current market expectations, with a resultant reduced operating loss compared to these expectations.

Β 

Paul Mines, Chief Executive, said:

Β 

"Revenue generation is strong in both divisions and, coupling this with the achievement of a small group EBITDA profit in the quarter, we are increasingly confident that 2015 will become a very significant milestone in Biome's development."

Β 

Β 

- Ends -

Β 

Β 

Β 

For further information please contact:

Β 

Biome Technologies plc

Β 

Paul Mines, Chief Executive Officer

Β 

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Β 

Β 

Β 

Allenby Capital

Β 

David Hart/Alex Brearley (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

Β 

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

Β 

Β 

Β 

FTI Consulting

Β 

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTDLLFBEFFLFBK
Date   Source Headline
27th Apr 20071:34 pmRNSResult of AGM
27th Apr 20071:32 pmRNSDirectorate Change
26th Apr 20071:42 pmRNSAnnual Information Update
13th Apr 200712:29 pmRNSDirector's Dealing
30th Mar 20071:32 pmRNSAnnual Report and Accounts
23rd Mar 20075:09 pmRNSNotifiable Interest
21st Mar 20077:03 amRNSPreliminary Results
14th Mar 20075:59 pmRNSHolding(s) in Company
26th Feb 20077:01 amRNSBoard Appointment
23rd Feb 20073:18 pmRNSHolding(s) in Company
30th Jan 20079:00 amRNSNotice of Results
18th Dec 20064:58 pmRNSTotal Voting Rights
8th Dec 200612:31 pmRNSNotifiable Interest
28th Nov 20063:32 pmRNSNotifiable Interest
17th Nov 20063:33 pmRNSNotifiable Interest
16th Nov 20069:02 amRNSNotifiable Interest
14th Nov 20064:37 pmRNSDirectorate Change
14th Nov 20064:09 pmRNSDirector/PDMR Shareholding
14th Nov 20064:03 pmRNSNotifiable Interest
14th Nov 20069:55 amRNSNotifiable Interest
10th Nov 200610:29 amRNSHolding(s) in Company
9th Nov 200611:45 amRNSNotifiable Interest
8th Nov 20063:08 pmRNSNotifiable Interest
7th Nov 20068:01 amRNSIssue of Equity
6th Nov 200612:12 pmRNSResult of EGM
3rd Nov 20064:41 pmRNSNotifiable Interest
3rd Nov 20061:17 pmRNSOpen Offer Result - Amendment
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.